Biotech News

"These acquisitions could take place in all of the businesses that we have," Chief Executive Karl-Ludwig Kley told Journalists at a press conference on Thursday.

Bausch + Lomb Inc.'s parent company said Thursday it had made further cuts to B+L's Rochester-area workforce.

Small stocks have brought big joy this year, but they've been so generous that some mutual fund managers question how much they have left to give.

Eli Lilly said Thursday its depression drug edivoxetine failed in late-stage clinical testing, and it doesn't plan to file for marketing approval of the drug.

New York Mayor Michael Bloomberg administration's is using its final days to cement its vision the city as an economic epicenter for the life sciences industry.

In this Thursday, Nov. 14, 2013, file photo, retired U.S. Air Force Master Sgt. Thomas Gipson, of Atlanta, right, has his resume looked over by Ralph Brown, a management and program analyst with the Centers for Disease Control and Prevention, during a job fair for veterans at the VFW Post 2681,Marietta, Ga.

The offer price represents a premium of 39 percent to the volume weighted average share price of Celesio during the three-month period ended October 7, 2013, which was the last undisturbed trading day before news articles were published suggesting a transaction between McKesson Corporation and Celesio.

Gilead Sciences Inc. Chairman and CEO John Martin netted nearly $19 million by selling 282,242 shares Monday at nearly 10 times the price at which he exercised options to buy the shares.

The Baltimore Development Corp. is offering a second round of job creation incentives to Rockville-based Emergent Biosolutions as the company prepares to expand its facility near Johns Hopkins Bayview Medical Center.

Pfizer has announced an update of its clinical trial data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials.

Medical instruments maker Harvard Bioscience said Wednesday that it will eliminate about 50 jobs, or 13 percent of its workforce, to save money and plans to reinvest some of the savings in expanding its business in China.

The report from Toronto-based Environmental Defence says the big five all have issues with chemicals that could be harmful to human health, but some are doing better than others.

Johnson & Johnson officials destroyed or misplaced documents related to its vaginal-mesh implants and should be barred from relying on some defenses in planned trials over the devices, patients' lawyers said.

Carbon monoxide is a colorless, odorless killer. E.R. physician Dr. Travis Stork explains symptoms of carbon monoxide poisoning and what to do if it happens to you.

Biotechnology stocks were among the most sought-after initial public offerings this year, with 38 through mid-November.

Novartis AG 's animal-health business is drawing interest from drugmakers including Eli Lilly & Co.

A man suspected of flying with tuberculosis tested negative for the disease, according to Maricopa County health officials, meaning there was never a risk to other passengers on his flight.

Denmark's Novo Nordisk has a stronger development pipeline of new drug candidates than it has ever had before, and thinks it can keep delivering the strong sales growth of the past decade, its chief executive said on Tuesday.

The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

Jon Bresler was an early supporter of the North American Free Trade Agreement. As owner of Suncook Woven Labels, a textile company whose customers included Ralph Lauren, The Gap and J.C. Penney, Bresler figured anything that would break down trade barriers between the United States, Mexico and Canada would be good for business.